Prostate volume index and prostatic chronic inflammation predicted low tumor load in 945 patients at baseline prostate biopsy.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 31 01 2019
accepted: 28 05 2019
pubmed: 4 6 2019
medline: 29 1 2021
entrez: 3 6 2019
Statut: ppublish

Résumé

To assess associations of prostate volume index (PVI), defined as the ratio of the volume of the central transition zone to the volume of the peripheral zone of the prostate and prostatic chronic inflammation (PCI) as predictors of tumor load by number of positive cores (PC) in patients undergoing baseline random biopsies. Parameters evaluated included age, PSA, total prostate volume, PSA density, digital rectal exam, PVI, and PCI. All patients underwent standard transperineal random biopsies. Tumor load was evaluated as absent (no PC), limited (1-3 PC), and extensive (more than 3 PC). The association of factors with the risk of tumor load was evaluated by the multinomial logistic regression model. The study evaluated 945 patients. Cancer PC were detected in 477 (507%) cases of whom 207 (43.4%) had limited tumor load and 270 (56.6%) had extensive tumor load. Among other factors, comparing patients with limited tumor load with negative cases, PVI [odds ratio, OR = 0.521, 95% confidence interval (CI) 0.330-0.824; p < 0.005] and PCI (OR = 0.289, 95% CI 0.180-0.466; p < 0.0001) were inversely associated with the PCA risk. Comparing patients with extensive tumor load with negative patients, PVI (OR = 0.579, 95% CI 0.356-0.944; p = 0.028), and PCI (OR = 0.150, 95% CI 0.085-0.265; p < 0.0001), predicted PCA risk. Comparing extensive tumor load with limited tumor load patients, PVI and PCI did not show any association with the tumor load. Increased PVI and the presence of PCI decreased the risk of increased tumor load and associated with less aggressive prostate cancer biology in patients at baseline random biopsies.

Identifiants

pubmed: 31154465
doi: 10.1007/s00345-019-02830-7
pii: 10.1007/s00345-019-02830-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

957-964

Références

Urol Int. 2017;98(1):22-27
pubmed: 27376763
Prostate. 2018 Jan;78(1):40-47
pubmed: 29105795
Urol Int. 2018;100(4):456-462
pubmed: 29672311
Abdom Radiol (NY). 2017 Apr;42(4):1255-1258
pubmed: 27858090
Ultrasound Med Biol. 1998 Jun;24(5):673-81
pubmed: 9695270
Urol Int. 2017;98(1):32-39
pubmed: 27798942
Urol Int. 2010;84(2):153-8
pubmed: 20215818
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
JAMA. 1999 Jul 21;282(3):236-7
pubmed: 10422990
Sci Rep. 2017 Aug 29;7(1):9763
pubmed: 28852180
Eur Urol. 2011 Jul;60(1):106-17
pubmed: 21497433
Int J Cancer. 2015 Oct 1;137(7):1749-57
pubmed: 25821151
Urol Clin North Am. 2016 Aug;43(3):289-97
pubmed: 27476122
Asian J Androl. 2015 Mar-Apr;17(2):212-6
pubmed: 25337845
Curr Opin Urol. 2017 Mar;27(2):99-106
pubmed: 27906778
Eur Urol. 2015 Jun;67(6):1099-1109
pubmed: 25613154
J Clin Oncol. 2005 Oct 20;23(30):7546-54
pubmed: 16234520
Curr Urol. 2017 Aug;10(3):118-125
pubmed: 28878593
Curr Urol. 2018 Feb;11(2):85-91
pubmed: 29593467
Tumori. 2017 May 12;103(3):299-306
pubmed: 27716882
World J Urol. 2012 Apr;30(2):149-55
pubmed: 22203238
Nat Rev Urol. 2018 Jan;15(1):11-24
pubmed: 29089606
J Urol. 2013 Jul;190(1):70-6
pubmed: 23313212
Tumori. 2017 Jul 31;103(4):374-379
pubmed: 28291903
Urol Int. 2015;94(3):270-85
pubmed: 25170543
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
J Urol. 2018 May;199(5):1174-1181
pubmed: 29246732
Nat Rev Urol. 2016 Sep 30;13(10):613-26
pubmed: 27686153
Urol Int. 2017;99(4):392-399
pubmed: 28486228
Tumori. 2017 Sep 18;103(5):475-482
pubmed: 27834470
Urol Int. 2017;99(2):207-214
pubmed: 28245480

Auteurs

Antonio B Porcaro (AB)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. drporcaro@yahoo.com.
Divisione Clinicizzata di Urologia, Dipartimento ad Attività Integrata di Chirurgia ed Oncologia - Pancreas Center, University of Verona, Policlinico GB Rossi, P.le LA Scuro, 10, 37134, Verona, Italy. drporcaro@yahoo.com.

Alessandro Tafuri (A)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA, USA.

Marco Sebben (M)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Giovanni Novella (G)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Tania Processali (T)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Marco Pirozzi (M)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Nelia Amigoni (N)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Riccardo Rizzetto (R)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Aliasger Shakir (A)

USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA, USA.

Arianna Mariotto (A)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Matteo Brunelli (M)

Department of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Maria Angela Cerruto (MA)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Giovanni Enrico Cacciamani (GE)

USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA, USA.

Filippo Migliorini (F)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Salvatore Siracusano (S)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Walter Artibani (W)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH